CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade Caribou Biosciences, Inc. - CRBU CFD

5.30
3.72%
0.06
Low: 5
High: 5.3
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.06
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.024874 %
Charges from borrowed part ($-0.99)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.024874%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.002651 %
Charges from borrowed part ($0.11)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.002651%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 5.11
Open* 5.08
1-Year Change* -44.96%
Day's Range* 5 - 5.3
52 wk Range 4.12-13.19
Average Volume (10 days) 515.24K
Average Volume (3 months) 9.90M
Market Cap 325.50M
P/E Ratio -100.00K
Shares Outstanding 61.30M
Revenue 13.85M
EPS -1.63
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 31, 2023 5.30 0.19 3.72% 5.11 5.30 4.98
Mar 30, 2023 5.11 -0.04 -0.78% 5.15 5.25 4.90
Mar 29, 2023 5.13 0.34 7.10% 4.79 5.18 4.67
Mar 28, 2023 4.69 0.03 0.64% 4.66 4.87 4.54
Mar 27, 2023 4.68 0.06 1.30% 4.62 4.78 4.49
Mar 24, 2023 4.62 0.38 8.96% 4.24 4.69 4.18
Mar 23, 2023 4.26 -0.11 -2.52% 4.37 4.43 4.10
Mar 22, 2023 4.32 -0.43 -9.05% 4.75 4.75 4.31
Mar 21, 2023 4.79 -0.08 -1.64% 4.87 4.90 4.74
Mar 20, 2023 4.85 -0.04 -0.82% 4.89 4.91 4.69
Mar 17, 2023 4.91 -0.02 -0.41% 4.93 5.02 4.80
Mar 16, 2023 5.02 -0.07 -1.38% 5.09 5.15 4.91
Mar 15, 2023 5.15 0.10 1.98% 5.05 5.25 5.02
Mar 14, 2023 5.18 -0.25 -4.60% 5.43 5.51 5.10
Mar 13, 2023 5.30 0.25 4.95% 5.05 5.34 5.02
Mar 10, 2023 5.14 -0.29 -5.34% 5.43 5.48 4.93
Mar 9, 2023 5.48 -0.35 -6.00% 5.83 5.85 5.33
Mar 8, 2023 5.85 0.02 0.34% 5.83 5.92 5.75
Mar 7, 2023 5.86 0.03 0.51% 5.83 6.04 5.70
Mar 6, 2023 5.77 -0.32 -5.25% 6.09 6.09 5.54

Caribou Biosciences, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019
Total revenue 13.851 9.598 12.361 5.788
Revenue 13.851 9.598 12.361 5.788
Total Operating Expense 120.25 74.993 48.485 40.093
Selling/General/Admin. Expenses, Total 38.02 24.322 14.06 16.458
Research & Development 82.23 52.255 34.425 23.635
Operating Income -106.399 -65.395 -36.124 -34.305
Interest Income (Expense), Net Non-Operating -0.133 0.14 -0.517 3.337
Other, Net 7.181 -1.347 0.514 0
Net Income Before Taxes -99.351 -66.602 -36.127 -30.968
Net Income After Taxes -99.421 -66.923 -34.308 -23.431
Net Income Before Extra. Items -99.421 -66.923 -34.308 -23.431
Net Income -99.421 -66.923 -34.308 -23.431
Income Available to Common Excl. Extra. Items -99.421 -66.923 -34.308 -23.431
Income Available to Common Incl. Extra. Items -99.421 -66.923 -34.308 -23.431
Diluted Net Income -99.421 -66.923 -34.308 -23.431
Diluted Weighted Average Shares 60.8011 60.2632 56.7092 56.7092
Diluted EPS Excluding Extraordinary Items -1.63518 -1.11051 -0.60498 -0.41318
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -1.63518 -1.1276 -0.60498 -0.41318
Unusual Expense (Income) 0 -1.584
Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
Total revenue 3.692 3.303 4.192 2.664 2.559
Revenue 3.692 3.303 4.192 2.664 2.559
Total Operating Expense 34.27 29.84 32.623 23.517 22.964
Selling/General/Admin. Expenses, Total 8.534 9.849 10.044 9.593 7.853
Research & Development 25.736 19.991 22.579 13.924 15.111
Operating Income -30.578 -26.537 -28.431 -20.853 -20.405
Interest Income (Expense), Net Non-Operating -0.06 0.031 -0.016 0.163 0.076
Other, Net 3.719 -0.141 1.75 1.602 2.171
Net Income Before Taxes -26.919 -26.647 -26.697 -19.088 -18.158
Net Income After Taxes -26.989 -26.647 -26.697 -19.088 -18.479
Net Income Before Extra. Items -26.989 -26.647 -26.697 -19.088 -18.479
Net Income -26.989 -26.647 -26.697 -19.088 -18.479
Income Available to Common Excl. Extra. Items -26.989 -26.647 -26.697 -19.088 -18.479
Income Available to Common Incl. Extra. Items -26.989 -26.647 -26.697 -19.088 -18.479
Diluted Net Income -26.989 -26.647 -26.697 -19.088 -18.479
Diluted Weighted Average Shares 61.01 60.8869 60.7577 60.5462 60.2632
Diluted EPS Excluding Extraordinary Items -0.44237 -0.43765 -0.4394 -0.31526 -0.30664
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.44237 -0.43765 -0.4394 -0.31526 -0.30664
Unusual Expense (Income) 0 0 0 0
  • Annual
  • Quarterly
2021 2020 2019
Total Current Assets 391.192 24.306 57.008
Cash and Short Term Investments 375.832 15.953 49.471
Cash & Equivalents 240.42 15.953 41.07
Short Term Investments 135.412 0 8.401
Total Receivables, Net 8.124 5.16 3.982
Accounts Receivable - Trade, Net 2.641 1.478 0.841
Prepaid Expenses 6.565 2.433 3.182
Other Current Assets, Total 0.671 0.76 0.373
Total Assets 442.356 36.046 61.933
Property/Plant/Equipment, Total - Net 4.887 3.502 4.332
Property/Plant/Equipment, Total - Gross 8.964 6.598 6.59
Accumulated Depreciation, Total -4.077 -3.096 -2.258
Long Term Investments 45.302 7.626 0
Other Long Term Assets, Total 0.975 0.612 0.593
Total Current Liabilities 25.829 12.389 10.078
Accounts Payable 3.99 2.601 2.537
Accrued Expenses 12.089 8.151 5.653
Notes Payable/Short Term Debt 0 0 0
Current Port. of LT Debt/Capital Leases 0 0.654 0
Other Current Liabilities, Total 9.75 0.983 1.888
Total Liabilities 54.531 18.16 13.147
Total Long Term Debt 0 0.924 0
Long Term Debt 0 0.924 0
Deferred Income Tax 0.476 0.155 0.65
Other Liabilities, Total 28.226 4.692 2.419
Total Equity 387.825 17.886 48.786
Preferred Stock - Non Redeemable, Net 0 41.323 41.323
Common Stock 0.006 0.001 0.001
Additional Paid-In Capital 485.748 7.433 4.025
Retained Earnings (Accumulated Deficit) -97.794 -30.871 3.437
Total Liabilities & Shareholders’ Equity 442.356 36.046 61.933
Total Common Shares Outstanding 60.2632 56.7092 56.7092
Other Equity, Total -0.135
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 368.01 391.192 449.047 142.967 155.925
Cash and Short Term Investments 353.731 375.832 435.31 129.524 145.924
Cash & Equivalents 147.63 240.42 435.31 129.524 145.924
Total Receivables, Net 6.037 8.124 7.785 8.407 5.825
Accounts Receivable - Trade, Net 1.868 2.641 2.431 0.832 1.049
Prepaid Expenses 7.276 6.565 5.189 3.759 3.096
Other Current Assets, Total 0.966 0.671 0.763 1.277 1.08
Total Assets 445.997 442.356 461.96 158.397 167.965
Property/Plant/Equipment, Total - Net 31.765 4.887 4.477 4.408 3.38
Property/Plant/Equipment, Total - Gross 36.15 8.964 8.282 7.952 6.695
Accumulated Depreciation, Total -4.385 -4.077 -3.805 -3.544 -3.315
Long Term Investments 44.758 45.302 7.626 7.626 7.626
Other Long Term Assets, Total 1.464 0.975 0.81 3.396 1.034
Total Current Liabilities 26.667 25.829 26.158 26.007 22.21
Accounts Payable 1.814 3.99 3.482 4.029 3.117
Accrued Expenses 11.215 12.089 12.288 11.034 10.929
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0 0 0.655
Other Current Liabilities, Total 13.638 9.75 10.388 10.944 7.509
Total Liabilities 74.2 54.531 57.559 55.938 53.504
Total Long Term Debt 0 0 0 0 0.926
Long Term Debt 0 0 0 0.926
Deferred Income Tax 0.476 0.476 0.155 0.155 0.155
Other Liabilities, Total 47.057 28.226 31.246 29.776 30.213
Total Equity 371.797 387.825 404.401 102.459 114.461
Preferred Stock - Non Redeemable, Net 0 0 0 150.15 150.15
Common Stock 0.006 0.006 0.006 0.001 0.001
Additional Paid-In Capital 489.762 485.748 483.71 10.649 8.34
Retained Earnings (Accumulated Deficit) -116.882 -97.794 -79.315 -58.341 -44.03
Total Liabilities & Shareholders’ Equity 445.997 442.356 461.96 158.397 167.965
Total Common Shares Outstanding 60.6896 60.2632 60.0213 59.9708 56.7092
Short Term Investments 206.101 135.412
Other Equity, Total -1.089 -0.135
  • Annual
  • Quarterly
2022 2021 2020 2019
Net income/Starting Line -99.421 -66.923 -34.308 -23.431
Cash From Operating Activities -90.966 -32.519 -33.215 -32.006
Cash From Operating Activities 1.622 0.984 0.9 0.751
Non-Cash Items 11.037 4.353 0.016 -1.059
Cash Taxes Paid 0 0.011 0.021 1.809
Changes in Working Capital -4.204 29.067 0.177 -8.267
Cash From Investing Activities -93.249 -176.397 6.363 27.233
Capital Expenditures -6.454 -2.121 -0.317 -0.884
Other Investing Cash Flow Items, Total -86.795 -174.276 6.68 28.117
Cash From Financing Activities 2.133 433.429 1.735 0.172
Issuance (Retirement) of Stock, Net 2.133 432.398 1.848 0.217
Issuance (Retirement) of Debt, Net 0 1.031 -0.113 -0.045
Net Change in Cash -182.082 224.513 -25.117 -4.601
Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
Net income/Starting Line -99.421 -72.432 -45.785 -19.088 -66.923
Cash From Operating Activities -90.966 -65.922 -43.546 -21.673 -32.519
Cash From Operating Activities 1.622 1.116 0.666 0.308 0.984
Non-Cash Items 11.037 9.47 4.942 2.215 4.353
Cash Taxes Paid 0 0 0 0 0.011
Cash Interest Paid 0
Changes in Working Capital -4.204 -4.076 -3.369 -5.108 29.067
Cash From Investing Activities -93.249 -94.419 -86.08 -72.107 -176.397
Capital Expenditures -6.454 -4.697 -3.343 -0.723 -2.121
Other Investing Cash Flow Items, Total -86.795 -89.722 -82.737 -71.384 -174.276
Cash From Financing Activities 2.133 2.006 1.352 0.99 433.429
Issuance (Retirement) of Stock, Net 2.133 2.006 1.352 0.99 432.398
Issuance (Retirement) of Debt, Net 0 0 0 0 1.031
Net Change in Cash -182.082 -158.335 -128.274 -92.79 224.513
Financing Cash Flow Items 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
PFM Health Sciences, LP Hedge Fund 7.2754 4459783 -1540217 2022-12-31 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.6832 4096777 277588 2022-12-31 LOW
Haurwitz (Rachel E. Ph.D.) Individual Investor 5.5129 3379395 10000 2023-03-20 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 5.2184 3198893 803423 2022-12-31 LOW
Avidity Partners Management LP Hedge Fund 4.7025 2882600 -290000 2022-12-31 HIGH
Rokos Capital Management LLP Hedge Fund 4.4831 2748139 840630 2022-12-31 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.1939 2570827 26789 2022-12-31 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 4.1662 2553878 -737020 2022-12-31 LOW
Elmwood Wealth Management, INC. Investment Advisor 3.8569 2364240 0 2022-12-31 LOW
EIDP Inc Corporation 3.3573 2058000 -1093311 2022-05-31 MED
BofA Global Research (US) Research Firm 3.008 1843902 1668395 2022-12-31 LOW
Fidelity Management & Research Company LLC Investment Advisor 2.3541 1443046 -547 2022-12-31 LOW
Morgan Stanley & Co. LLC Research Firm 1.982 1214933 30615 2022-12-31 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.6819 1030987 45617 2022-12-31 LOW
Alkeon Capital Management LLC Investment Advisor/Hedge Fund 1.4575 893424 -138016 2022-12-31 LOW
Fidelity International Investment Advisor 1.404 860666 0 2022-12-31 LOW
Assenagon Asset Management S.A. Investment Advisor 1.3944 854738 55247 2022-12-31 HIGH
Maverick Capital, Ltd. Hedge Fund 1.0645 652542 0 2022-12-31 MED
Tekla Capital Management LLC Investment Advisor 0.9252 567147 0 2022-12-31 LOW
JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 0.9215 564855 -1059 2022-12-31 LOW

Start a global, multi-asset portfolio with an award-winning platform

Trade now Desktop

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Caribou Biosciences, Inc. Company profile

About Caribou Biosciences Inc

Caribou Biosciences, Inc. is a United States-based clinical-stage biotechnology company. The Company uses clustered regularly interspaced short palindromic repeats (CRISPR) genome editing to discover and develop immune cell-based therapeutics for cancer. It is focused on developing a pipeline of genome-edited off-the-shelf CAR-T cell and natural killer (NK) cell therapies for a range of tumor types. It also offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics and industrial biotechnology. The Company's pipeline includes CB-010, CB-011, CB-012 and CB-020.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Caribou Biosciences Inc revenues totaled $7M. Net loss totaled to $48.4M.

Industry: Biotechnology & Medical Research (NEC)

2929 7Th Street, Ste 120
BERKELEY
CALIFORNIA 94710
US

Income Statement

  • Annual
  • Quarterly

News

A file photo shows a part of a stack of 500 Canadian gold coins, worth $1 million USD according to Sprott Money, is displayed at the precious metals dealer's booth at the Prospectors and Developers Association of Canada (PDAC) annual conference in Toronto

PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise

Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.

09:37, 31 March 2023
People use DBS automated teller machines (ATMs) in Singapore March 31, 2022.

Singapore's DBS has seen inflows in SVB aftermath, CEO says

DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.

09:24, 31 March 2023
Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., March 29, 2023.

US STOCKS-Futures muted as investors await key inflation data

U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.

09:16, 31 March 2023
A file photo of the logo of Australian energy company Origin pictured in Melbourne, Australia, July 3, 2016

Asia M&As drop to decade low as tumultuous backdrop deters dealmaking

Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.

09:14, 31 March 2023
A file photo of a worker shoveling coal in a supply truck at a yard on the outskirts of Ahmedabad, India, October 25, 2018.

Coal India surpasses annual output target for first time in 17 years

Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.

09:13, 31 March 2023
A file photo of bull and bear symbols in front of the German stock exchange in Frankfurt, Germany, February 12, 2019.

Global IPOs marred by banks and recession enjoy few bright spots

A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.

09:06, 31 March 2023
A file photo of Unicredit Bank logo seen in this illustration taken March 12, 2023.

UniCredit shareholders gather to vote on CEO's new pay scheme

Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.

09:04, 31 March 2023

People also watch

Gold

1,969.66 Price
-0.550% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0102%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

13,186.80 Price
+1.680% 1D Chg, %
Long position overnight fee -0.0249%
Short position overnight fee 0.0027%
Overnight fee time 21:00 (UTC)
Spread 3.0

Natural Gas

2.20 Price
+3.540% 1D Chg, %
Long position overnight fee -0.4092%
Short position overnight fee 0.3873%
Overnight fee time 21:00 (UTC)
Spread 0.005

Oil - Crude

75.76 Price
+1.830% 1D Chg, %
Long position overnight fee -0.0156%
Short position overnight fee -0.0063%
Overnight fee time 21:00 (UTC)
Spread 0.03

Still looking for a broker you can trust?

Join the 500.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading